BDM 10:21 AM BioDiem completes recruitment of patients for clinical trial
http://www.asx.com.au/asxpdf/20070430/pdf/3125py0kj04v57.pdf
BioDiem completes recruitment of patients for its clinical trial in
diabetic eye disease
Australian biopharmaceutical development company BioDiem Ltd (ASX:BDM)
announced today it has completed recruitment of 192 patients in a phase I/II clinical trial of its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.
Commenting on this milestone today, BioDiem Chief Executive Officer, Tom Williams said, “It’s pleasing to have completed this significant step in executing the clinical trial. We now expect to report on the result of the trial during Q4, CY 2007.”
- Forums
- ASX - By Stock
- BDM
- asx ann april 30
BDM
burgundy diamond mines limited
Add to My Watchlist
0.00%
!
2.2¢

asx ann april 30
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $31.26M |
Open | High | Low | Value | Volume |
2.2¢ | 2.2¢ | 2.2¢ | $819 | 37.20K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 884140 | 2.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.4¢ | 383415 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 884140 | 0.021 |
4 | 1580000 | 0.020 |
2 | 173157 | 0.019 |
1 | 5000 | 0.018 |
1 | 197000 | 0.017 |
Price($) | Vol. | No. |
---|---|---|
0.024 | 383415 | 3 |
0.026 | 519866 | 2 |
0.030 | 328281 | 3 |
0.031 | 300000 | 1 |
0.032 | 1300000 | 2 |
Last trade - 13.07pm 15/09/2025 (20 minute delay) ? |
Featured News
BDM (ASX) Chart |
The Watchlist
3DA
AMAERO LTD
Hank Holland, Chairman and CEO
Hank Holland
Chairman and CEO
Previous Video
Next Video
SPONSORED BY The Market Online